{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:50:39Z","timestamp":1769763039492,"version":"3.49.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T00:00:00Z","timestamp":1397606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cjca.2014.03.003","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T07:46:14Z","timestamp":1394005574000},"page":"S29-S37","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S","title":["Nebivolol: Vasodilator Properties and Evidence for Relevance in Treatment of Cardiovascular Disease"],"prefix":"10.1016","volume":"30","author":[{"given":"Jonathan G.","family":"Howlett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2014.03.003_bib1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacc.2009.05.066","article-title":"Nebivolol: the somewhat-different beta-adrenergic receptor blocker","volume":"54","author":"Munzel","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/00005344-198805000-00007","article-title":"Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist","volume":"11","author":"Van de Water","year":"1988","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2014.03.003_bib3","first-page":"S37","article-title":"Beta-blocking agents with vasodilator activity","volume":"11","author":"Rosendorff","year":"1993","journal-title":"J\u00a0Hypertens Suppl"},{"key":"10.1016\/j.cjca.2014.03.003_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1527-3466.2008.00044.x","article-title":"Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol","volume":"26","author":"Ignarro","year":"2008","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2014.03.003_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1023\/A:1007760515117","article-title":"Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure","volume":"12","author":"Van Nueten","year":"1998","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjca.2014.03.003_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1755-5922.2008.00054.x","article-title":"Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide","volume":"26","author":"Gupta","year":"2008","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2014.03.003_bib7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1751-7176.2008.06632.x","article-title":"Vascular system: role of nitric oxide in cardiovascular diseases","volume":"10","author":"Bian","year":"2008","journal-title":"J\u00a0Clin Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s12272-009-1801-1","article-title":"Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases","volume":"32","author":"Napoli","year":"2009","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.cjca.2014.03.003_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/00005344-199106000-00016","article-title":"Nebivolol induces endothelium-dependent relaxations of canine coronary arteries","volume":"17","author":"Gao","year":"1991","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2014.03.003_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/08038020410016557","article-title":"Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker","volume":"1","author":"Ignarro","year":"2004","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.cjca.2014.03.003_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijcard.2007.11.095","article-title":"The anti-inflammatory effects of nebivolol in human coronary smooth muscle cells: clinical implications","volume":"133","author":"Celik","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/VHRM.S20669","article-title":"Nebivolol: impact on cardiac and endothelial function and clinical utility","volume":"8","author":"Toblli","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.cjca.2014.03.003_bib13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1253\/circj.72.660","article-title":"The effects of nebivolol on apoptosis in a rat infarct model","volume":"72","author":"Mercanoglu","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.cjca.2014.03.003_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/HJH.0b013e328337598c","article-title":"Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats","volume":"28","author":"Toblli","year":"2010","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejvs.2013.11.003","article-title":"The effect of different beta-blockers on vascular graft nitric oxide levels: comparison of nebivolol versus metoprolol","volume":"47","author":"Bayar","year":"2014","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.cjca.2014.03.003_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00051145","article-title":"Exercise tolerance with nebivolol and atenolol","volume":"6","author":"Van Bortel","year":"1992","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjca.2014.03.003_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/1753944709345926","article-title":"Regional functions of the left ventricle in patients with coronary slow flow and the effects of nebivolol","volume":"3","author":"Gunes","year":"2009","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2014.03.003_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00380-009-1170-1","article-title":"Effects of nebivolol therapy on endothelial functions in cardiac syndrome X","volume":"25","author":"Kayaalti","year":"2010","journal-title":"Heart Vessels"},{"key":"10.1016\/j.cjca.2014.03.003_bib19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0167-5273(94)90208-9","article-title":"Determination of the anti-ischemic activity of nebivolol in comparison with atenolol","volume":"43","author":"Ruf","year":"1994","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib20","first-page":"371","article-title":"Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X","volume":"9","author":"Sen","year":"2009","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.1016\/j.cjca.2014.03.003_bib21","first-page":"56","article-title":"Antiischemic and metabolic effects of nebivolol and metaprolol CR\/XL (betalok ZOK) in patients with postinfarction heart dysfunction [in Russian]","volume":"83","author":"Tepliakov","year":"2005","journal-title":"Klin Med Mosk"},{"key":"10.1016\/j.cjca.2014.03.003_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.jhh.1000571","article-title":"Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial","volume":"12","author":"Van Nueten","year":"1998","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.113.01302","article-title":"Differential effects of nebivolol versus metoprolol on functional sympatholysis in hypertensive humans","volume":"61","author":"Price","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2014.03.003_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1755-5922.2011.00261.x","article-title":"Effects of beta-blockade on exercise performance at high altitude: a randomized, placebo-controlled trial comparing the efficacy of nebivolol versus carvedilol in healthy subjects","volume":"30","author":"Valentini","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2014.03.003_bib25","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0735-1097(01)01577-7","article-title":"Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol","volume":"38","author":"Kubo","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/hc3001.094207","article-title":"Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study","volume":"104","author":"Tzemos","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.03.003_bib27","first-page":"45","article-title":"Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients","volume":"14","author":"Simova","year":"2009","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.03.003_bib29","first-page":"1359","article-title":"Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial","volume":"15","author":"Caglar","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cjca.2014.03.003_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.amjhyper.2004.08.039","article-title":"Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan","volume":"18","author":"Fountoulaki","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/1074248413484986","article-title":"\u03b2-Adrenergic blockade in cardiovascular disease","volume":"18","author":"Frishman","year":"2013","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cjca.2014.03.003_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2012.03.2532","article-title":"Vasodilating versus first-generation \u03b2-blockers for cardiovascular protection","volume":"124","author":"Fares","year":"2012","journal-title":"Postgrad Med"},{"key":"10.1016\/j.cjca.2014.03.003_bib33","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.amjhyper.2005.06.011","article-title":"Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study","volume":"18","author":"Galzerano","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib34","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ajh.2012.81","article-title":"Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study","volume":"25","author":"Greve","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib35","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.03.003_bib36","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ajh.2008.156","article-title":"Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection","volume":"21","author":"Mahmud","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jash.2013.09.001","article-title":"Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness","volume":"8","author":"Koumaras","year":"2014","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/HJH.0b013e3283442f37","article-title":"Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol","volume":"29","author":"Vinereanu","year":"2011","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00045391-199406000-00012","article-title":"A\u00a0double-blind crossover comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension","volume":"1","author":"Lacourciere","year":"1994","journal-title":"Am J Ther"},{"key":"10.1016\/j.cjca.2014.03.003_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00129784-200808010-00005","article-title":"Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis","volume":"8","author":"Van Bortel","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cjca.2014.03.003_bib41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jacc.2006.10.059","article-title":"Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET","volume":"49","author":"Remme","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1753944710387629","article-title":"Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial","volume":"4","author":"Punzi","year":"2010","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2014.03.003_bib43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ajh\/7.2.137","article-title":"Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial","volume":"7","author":"Lacourciere","year":"1994","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib44","first-page":"283","article-title":"Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients","volume":"8","author":"Lacourciere","year":"1994","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/HJH.0b013e3282f283c9","article-title":"A\u00a0comparison of atenolol and nebivolol in isolated systolic hypertension","volume":"26","author":"Dhakam","year":"2008","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib46","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjhyper.2005.03.733","article-title":"Quality of life and antihypertensive effect with nebivolol and losartan","volume":"18","author":"Van Bortel","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1026180325278","article-title":"Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS)","volume":"17","author":"Czuriga","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjca.2014.03.003_bib48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.110.169169","article-title":"\u03b2-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial","volume":"58","author":"Espinola-Klein","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2014.03.003_bib49","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.repc.2012.04.016","article-title":"Resolution of nebivolol-induced coronary vasospasm by intracoronary nitroglycerin during a coronary angiogram","volume":"31","author":"Akkus","year":"2012","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib50","first-page":"290","article-title":"The effects of nebivolol on P wave duration and dispersion in patients with coronary slow flow","volume":"9","author":"Gunes","year":"2009","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.1016\/j.cjca.2014.03.003_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.niox.2008.03.004","article-title":"Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits","volume":"19","author":"de Nigris","year":"2008","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.cjca.2014.03.003_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00005344-200201000-00009","article-title":"Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat","volume":"39","author":"Sia","year":"2002","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2014.03.003_bib53","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/MCA.0b013e32830936bb","article-title":"The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X","volume":"20","author":"Erdamar","year":"2009","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.cjca.2014.03.003_bib54","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1136\/hrt.2005.084079","article-title":"Different effects of atenolol and nebivolol on coronary flow reserve","volume":"92","author":"Gullu","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2014.03.003_bib55","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1097\/HJH.0b013e32832ea925","article-title":"Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension","volume":"27","author":"Galderisi","year":"2009","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib56","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cjca.2013.01.005","article-title":"The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"29","author":"Hackam","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.03.003_bib58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/hrt.2010.207365","article-title":"\u03b2-Blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure","volume":"97","author":"Ambrosio","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2014.03.003_bib59","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/000331979004100904","article-title":"Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure","volume":"41","author":"Brune","year":"1990","journal-title":"Angiology"},{"key":"10.1016\/j.cjca.2014.03.003_bib60","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1071-9164(97)90026-9","article-title":"Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial","volume":"3","author":"Uhlir","year":"1997","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2014.03.003_bib61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study","volume":"14","author":"Conraads","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2014.03.003_bib62","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1388-9842(03)00054-0","article-title":"Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol","volume":"5","author":"Nodari","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2014.03.003_bib63","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ijcard.2013.01.277","article-title":"Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial","volume":"168","author":"Contini","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib64","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ahj.2005.07.024","article-title":"Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study","volume":"150","author":"Patrianakos","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2014.03.003_bib65","first-page":"199","article-title":"Effects of nebivolol on left ventricular function and exercise capacity in patients with non-ischaemic dilated cardiomyopathy. A randomised placebo-controlled study","volume":"46","author":"Patrianakos","year":"2005","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00129784-200606040-00006","article-title":"Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function","volume":"6","author":"Lombardo","year":"2006","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cjca.2014.03.003_bib67","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib68","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.03.003_bib69","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.03.003_bib70","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.03.003_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.03.003_bib72","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cjca.2012.10.007","article-title":"The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure","volume":"29","author":"McKelvie","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib73","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.03.003_bib74","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.03.003_bib75","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.03.003_bib76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.03.003_bib77","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A\u00a0trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.03.003_bib78","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.03.003_bib79","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/eurheartj\/ehi735","article-title":"Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy","volume":"27","author":"Ghio","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.03.003_bib80","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib81","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/joim.12141","article-title":"The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF","volume":"275","author":"Wikstrand","year":"2014","journal-title":"J\u00a0Int Med"},{"key":"10.1016\/j.cjca.2014.03.003_bib82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00151642-200512010-00005","article-title":"Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective B-blockers in the treatment of hypertension","volume":"12","author":"Ambrosioni","year":"2005","journal-title":"High Blood Press Cardiovasc Rev"},{"key":"10.1016\/j.cjca.2014.03.003_bib83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1755-5922.2009.00123.x","article-title":"Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents","volume":"28","author":"Cordero","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2014.03.003_bib84","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1097\/HJH.0b013e328339f9fa","article-title":"Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice","volume":"28","author":"Corrao","year":"2010","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib85","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1440-1681.2007.04551.x","article-title":"Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men","volume":"34","author":"Brixius","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cjca.2014.03.003_bib86","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00044011-200525060-00006","article-title":"A\u00a0randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men","volume":"25","author":"Boydak","year":"2005","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cjca.2014.03.003_bib87","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/HJH.0b013e32834550d0","article-title":"Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class","volume":"29","author":"Mancia","year":"2011","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.03.003_bib88","first-page":"153","article-title":"Compliance and persistence with nebivolol vs. diuretics as first add-on hypertension treatment","volume":"14","author":"Chen","year":"2013","journal-title":"J\u00a0Clin Hypertens"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1400141X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1400141X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T01:06:45Z","timestamp":1565226405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X1400141X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0828282X1400141X"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2014.03.003","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}